Hepatocellular Carcinoma Update, Issue 1, 2020 — Part 1: Our
interview with Dr Harding highlights the following topics as well
as cases from his practice:
Clinical experience with immune checkpoint inhibitors for
patients with hepatocellular carcinoma (HCC) (00:00)
Immune-related adverse events associated with immune checkpoint
inhibitors (01:43)
Activity of nivolumab or pembrolizumab as monotherapy for HCC
(04:29)
Biologic rationale for combining immune checkpoint inhibitors
and anti-angiogenic agents; results of the IMbrave150 study
evaluating atezolizumab/bevacizumab as first-line therapy for
unresectable HCC (07:45)
Side effects of the atezolizumab/bevacizumab combination in
IMbrave150 (10:06)
Risk of bleeding, cardiovascular disease, hypertension and
proteinuria with the use of bevacizumab (13:05)
Perspective on the use of atezolizumab/bevacizumab for patients
with liver dysfunction (15:30)
Objective response rate with atezolizumab/bevacizumab versus
sorafenib in the IMbrave150 study (17:26)
Potential role of combination immunotherapy approaches versus
locoregional modalities in the management of HCC (20:11)
Novel strategies under investigation for the treatment of HCC
(22:58)
Case: A man in his early 50s with a history of
hepatitis B receives atezolizumab/bevacizumab as first-line therapy
for metastatic HCC (25:36)
Role of biopsy for patients with HCC; incidence of metastatic
disease at first diagnosis (27:23)
Activity of atezolizumab/bevacizumab as first-line therapy
(31:39)
Tolerability of the atezolizumab/bevacizumab combination
(33:49)
Case: A man in his early 70s with metastatic
HCC and nonalcoholic steatohepatitis-associated cirrhosis receives
lenvatinib (36:23)
Use of immune checkpoint inhibitors for patients with
preexisting autoimmune disease (39:17)
Efficacy and safety of lenvatinib in combination with
pembrolizumab for patients with unresectable HCC (42:17)
Emerging data with nivolumab/ipilimumab and
tremelimumab/durvalumab for advanced HCC (45:01)
Risks and benefits with anti-PD-1/PD-L1 and anti-CTLA-4
combinations versus immune checkpoint inhibitor and anti-angiogenic
combinations (47:54)
Therapeutic options for patients with HCC in the second-line
setting (50:20)
Case: A man in his early 70s with advanced
hepatitis C-associated HCC receives cabozantinib after experiencing
disease progression on sorafenib (53:30)
Perspective on the role of immune checkpoint inhibitors alone
or in combination with anti-angiogenic therapy after disease
progression on sorafenib (55:07)
Clinical experience with and management of tyrosine kinase
inhibitor-associated toxicities (58:11)
Case: A woman in her late 70s with metastatic
HCC develops myasthenia gravis after treatment with nivolumab
(1:02:08)
Case: A woman in her late 50s with hepatitis
B-associated metastatic HCC experiences a delayed response to
nivolumab after enrolling in hospice care (1:06:06)
Delayed responses, pseudoprogression and hyperprogression
associated with immune checkpoint inhibitors (1:10:12)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.